Nanomaterials that mimic the catalytic activity of natural enzymes in the complex biological environment of the human body are called nanozymes. Recently, nanozyme systems have been reported with diagnostic, imaging, and/or therapeutic capabilities. Smart nanozymes strategically exploit the tumor microenvironment (TME) by the in situ generation of reactive species or by the modulation of the TME itself to result in effective cancer therapy. This topical review focuses on such smart nanozymes for cancer diagnosis, and therapy modalities with enhanced therapeutic effects. The dominant factors that guide the rational design and synthesis of nanozymes for cancer therapy include an understanding of the dynamic TME, structure‐activity relationships, surface chemistry for imparting selectivity, and site‐specific therapy, and stimulus‐responsive modulation of nanozyme activity. This article presents a comprehensive analysis of the subject including the diverse catalytic mechanisms of different types of nanozyme systems, an overview of the TME, cancer diagnosis, and synergistic cancer therapies. The strategic application of nanozymes in cancer treatment can well be a game changer in future oncology. Moreover, recent developments may pave the way for the deployment of nanozyme therapy into other complex healthcare challenges, such as genetic diseases, immune disorders, and ageing.
1 February 2022 in Current Opinion in Electrochemistry
The solution-based synthesis of the coordination polymer, CuTCNQ (TCNQ = 7,7,8,8-tetracyanoquinodimethane), which exists in two phases, has predominately used acetonitrile (MeCN) as the solvent. However, our knowledge on the growth and properties of CuTCNQ in other solvents remains limited. In this work, the synthesis of CuTCNQ on Cu foil in two protic (MeOH, EtOH) as well as four aprotic (MeCN, DMSO, DMF, THF) solvents has allowed us to obtain new insights into the important role of the reaction medium in the spontaneous crystallization of CuTCNQ in discrete morphologies and phases. A new electrochemical method for phase identification also has been developed to support this study. Findings reveal that (i) the solvents with higher dielectric constants favor CuTCNQ crystallization; (ii) irrespective of the solvent, use of high temperature (60 °C vs. 25 °C in conventional synthesis) promotes CuTCNQ crystallization and facilitate conversion of phase I to phase II; (iii) phase I CuTCNQ possess enhanced redox catalysis (ferricyanide reduction by thiosulfate) performance over phase II CuTCNQ; and (iv) the amount of catalyst is not necessarily the most important factor for driving catalytic reactions, and other factors, such as, morphology, redox characteristics and solvent in which the CuTCNQ is synthesized may dictate the overall catalytic performance. These findings emphasize the importance of understanding the influence of parameters, such as, solvent and temperature in CuTCNQ synthesis as a means of providing materials with improved catalytic activity.